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Aim: To evaluate treatment details, outcome, relapse rate and side-effects in Stage IIA semi-
noma  irradiated and followed for a period of 39 years.
Background: Seminoma is a very radiosensitive disease and radiation therapy alone is able
to  achieve long-term disease-free survival, even in advanced Stage disease. Due to the lack
of  long-term prospective studies, it is of value to follow patients and try to determine the
appropriate volume to be irradiated and the dose which can achieve total cure with minimal
acute and chronic side-effects.
Patients and methods: A retrospective review of 24 Stage IIA seminoma patients irradiated
between 1971 and 2010 was performed. All patients underwent orchiectomy and meticulous
clinical, biochemical and radiological staging.
Results: Median age at diagnosis was 36 years and median follow-up was 84 months. A major-
ity  of patients received the “hockey-stick” irradiation schedule (para-aortic lymph nodes and
hemi-pelvis) to a total dose of 2250–2500 cGy and a boost to radiologically involved nodes
of  500–1000 cGy. Treatment was well-tolerated. Twenty-one (88%) patients are alive with no
evidence of disease. Two patients died due to unknown causes, while one patient died due
to  head of the pancreas carcinoma, most probably radiation-induced.
Conclusions: In Stage II seminoma, radiotherapy can provide excellent results with low ratesof  toxicity. Reduction of total dose and size of ﬁelds without affecting the good results should
be  considered. Due to prolonged survival, awareness of second primary tumor is indicated.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.∗ Corresponding author at: Northern Israel Oncology Center, POB 9602, 
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Table 1 – Anamnestic details, symptoms, diagnostic and
therapeutic measures.
Age [years], median, range 36, 23–58
# of patients
Religion
Jews 22
Moslem 1
Christian 1
Ethnic origin
Ashkenazi Jews 23
Sephardic Jews 1
Place of birth
Israel 17
Europe 3
North Africa 2
North America 2
Referring hospital
Rambam 10
Jerusalem (Hadassah) 4
Safed 3
Nahariya 3
Haifa (Bnei-Zion) 2
Haemek 2
Etiology
Cryptorchidismus 2
Torsion 1
Side of tumor
Left 16
Right 6
Bilateral 2
Symptoms
Hard, painful testicle 5
Testicular swelling 12
Slow growing, painless mass 7
Duration of symptoms (months)
Median 77
Range 1–12
Work-up
Tumor markersa
-HCG 23
LDH 6
Radiology
Testicular US 15
CT scan 23
PET-CT 9
Lympho-angiography 7
Abdominal US 2
Mode of surgery
Inguinal orchiectomy 23b
Scrotal orchiectomy 1
Pathology
Classical seminoma 23
Anaplastic seminoma 1
ITGCN 7c
Stage of disease
IIA 24
Schedule of radiotherapy
total/daily dose (cGy)/# treatments
Hockey Stick
2500/125/20 11
3000/200/15 2
2550/170/15 3282  reports of practical oncology an
1.  Background
Testicular seminoma accounts for 40% of primary testicular
neoplasms, with 70–85% of patients presenting with disease
conﬁned to the testis (Stage I), while 15–20% present with
infra-diaphragmatic lymphadenopathy (Stage II).1 Due to the
high radiosensitivity of seminoma, radiotherapy has become
the mainstay of treatment in limited nodal involvement.1,2
Cause-speciﬁc survival usually exceeds 90% and, in recent
years, has been approaching 100%. Relapse rates reported in
the literature vary according to stage and treatment modality
with 11%, 19%, and 39% in Stage IIA, IIB, and IIC, respectively.1
Stage IIB (2–5 cm in size lymph nodes) can be treated suc-
cessfully with platinum-based chemotherapy or high-dose
radiotherapy to high-volume ﬁelds with chemotherapy held
for relapse. In this retrospective study, we  review our clinic’s
experience in radiotherapy treatment, outcome and toxicity
in 24 Stage IIA post-orchiectomy seminoma patients over a
period of 39 years.
2.  Patients  and  methods
We  report the radiotherapy treatment of 24 Stage IIA testicular
seminoma patients, treated successfully with radiotherapy.
Median age at diagnosis was 36 years (range, 23–58 years)
(Table 1
). Preoperative staging consisted of family history,
anamnestic details concerning prior diseases or surgical
procedures in pelvic or inguinal regions, physical and neu-
rologic examination, testicular ultrasound, blood count,
biochemistry proﬁle including measurement of B-human-
choriogonadotropin (-HCG), alpha-feto-protein (AFP) and
lactate dehydrogenase (LDH) (Table 2). The majority of patients
presented preoperatively with painless testicular swelling or
mass for a mean duration of symptoms of three months. Post-
orchiectomy staging consisted of whole-body computerized
tomography (CT scan) for all patients diagnosed after 1980.
In the last 10 years, eight patients have undergone ﬂuoro-
deoxyglucose positron emission tomography (PET-CT) as a
part of staging. Before 1980, lymphography was used as the
main goal of staging. Staging was determined using the Amer-
ican Joint Committee on Cancer (AJCC), 7th edition: Stage
IIA with pathologic abdomino-pelvic lymphadenopathy up to
2 cm in size.
Radiotherapy was delivered either with cobalt-60-
teletherapy (two patients before 1994) or with 6–18 MV
linear accelerator (Linac). Treatment decision parameters
and irradiated volume were done according to Wilder et al.3
Irradiated volume included the para-aortic lymph nodes
(upper ﬁeld: interface T12/T11; lower border: bottom of L5;
width: 9–11 cm). The ipsilateral hemipelvis was irradiated
(“hockey-stick” method) in 20 (83%) patients, with the lower
border downward to the mid-obturator level. Since 1990,
the hemipelvis ﬁeld has been omitted and the lower border
set at the cranial rim of the ipsilateral acetabulum (Fig. 1A
and B).4 The whole pelvis (“inverted-Y” method) was irradi-
ated in three patients due to scrotal violation and previous
inguinal repair in the presence of an undescended testis.
2550/150/17 1
2250/150/15 1
2250/170/13 1
2000/125/16 1
reports of practical oncology and radio
Table 1 (Continued)
# of patients
Inverted Y
2400/200/17 1
3000/200/15 1
4000/250/16 1
Upper/lower abdomen
1250/125/10 1d
Boost (involved lymph nodes)
1000/200/5 4
1000/125/8 6
510/170/3 5
600/200/3 2
1400/125/12 1
450/150/3 1
900/150/6 1
500/125/4 2
Boost to scrotum
2600/200/13 1
Mediastinum/supraclavicular grooves
3500/250/14 1
3000/200/15 1
a Alpha-feto-protein was negative in all patients.
b Patient #3 initially underwent biopsy from an inguinal mass which
proved to be an undescended testicle and then orchiectomy.
c Intratubular germ cell neoplasm.
d Retrospectively, it was IIB disease. Besides the upper/lower
abdomen, scrotal (3000 cGy/200/15) and para-aortic/pelvic regions
were also boosted with 2000 cGy (100 cGy daily fraction). Medi-
astinum/both supraclavicular grooves received a total dose of
T
o
2
f
b
t
out interruption. Acute side effects were mild and dominated
F
p3000 cGy (daily fraction 200 cGy).
otal dose ranged from 2000 to 4000 cGy, with daily fractions
f 200–250 cGy.
Since 1980, dosages have been in the range of
250–2550 cGy, with a total dose median of 2500 cGy (daily
ractions of 150–200 cGy). Treatment was followed by a
oost to the involved lymph nodes. Patients were boosted
o a range of 450–1400 cGy (median, 900 cGy; daily fractions
ig. 1 – Treatment portal used for Stage IIA seminoma: primary p
lus boost to radiologically involved lymph nodes (B).therapy 1 9 ( 2 0 1 4 ) 281–286 283
125–200 cGy). Two patients received prophylactic mediastinal
and supraclavicular irradiation ranging from 3000 to 3500 cGy
(daily fractions 200–250 cGy). One patient was irradiated to the
upper/lower abdomen to a total dose of 1250 cGy with daily
fractions of 125 cGy. One patient was boosted to the scrotum
(total dose of 2600 cGy; with daily fractions of 200 cGy).
Generally, patients were followed by three-monthly inter-
vals for the ﬁrst two years with physical examination, serum
tumor markers and chest X-rays (CXR), and CT scan of the
abdomen/pelvis. Thereafter, follow-up was continued at six-
monthly intervals to year 5 and annually beyond this.
Overall survival (OS) was determined from the date of
radiotherapy completion to the last available clinical follow-
up. The latest date and status were evaluated directly via the
Ministry of Internal Affairs (Fig. 2).
3.  Results
Between January 1971 and March 2010, 24 Stage IIA seminoma
patients were included in this retrospective study. Median
time to follow-up was 84 months (range, 42–282 months).
Median age was 36 years (range, 23–58 years). The majority
(90%) were of Jewish ancestry and Israeli-born (75%). Cryp-
torchidismus as an etiologic factor was observed in two
patients. A left-sided tumor was observed in 16 patients, right-
sided in six, and there were two patients with bilateral tumors.
All patients presented with swelling or a palpable hard testi-
cular mass and US demonstrated the typical ultrasonographic
features of a malignancy. Mean duration of symptoms was in
the range of 1–12 months. Seven patients were diagnosed with
incidental ITGC in addition to their seminoma, ﬁndings which
did not inﬂuence negatively their prognosis.
All patients completed their scheduled radiotherapy with-by grade I nausea and temporary weakness. Late toxicity is
shown in Table 2. Only one patient (#9) developed a second pri-
mary; three years after completion of his scheduled radiation
ara-aortic and ipsilateral, upper iliacal lymph nodes (A)
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Table 2 – Treatment schedule, side effects and follow-up.
Pt. no. Radiotherapy schedule Dose (total/daily fractions/no. of fractions)
Facility Plan Side effects Latest date Status
1. 18 MV
18 MV
1.  Hockey-stick
2. Boost
3000/200/15
600/200/3
2nd  primary
radiation-induced
pancreatic
carcinoma
19/05/2002 DODa
2. 6 MV
6  MV
1.  Hockey-stick
2. Boost
2250/170/13
510/170/3
Peptic  ulcer disease 23/03/2010 NEDa
3. 6 MV
6  MV
1.  Hockey-stick
2. Boost
2550/170/15
510/170/3
Radiation-induced
proctitis (mild form)
13/12/2009 NEDa
4. 6 MV
CO60
6 MV
Upper abdomen
Lower abdomen
Par-aortic + pelvis
Scrotum
Mediastinum + supraclavicular
grooves
1250/125/10
1250/125/10
2000/100/10
3000/200/15
3000/200/15
Chronic abdominal
pain
18/02/1988 NEDa
5. 18 MV
18 MV
1.  Hockey-stick
2. Boost
2500/125/20
500/125/4
Neutropenia,
thrombocytopenia
01/12/2012 NEDa
ce ofa DOD = dead of disease (radiation-induced primary); NED = no eviden
therapy, he developed a Helicobacter positive duodenal ulcer
and was treated conservatively. Three years later, the ulcer
recurred massively with perforation. The patient underwent
emergency laparotomy which revealed massive pancreas
head carcinoma, involving the ulcerated part of the duode-
num. A Whipple procedure was accomplished successfully
but his tumor recurred abdominally some months later, he
deteriorated and died. Reviewing the records of the Ministry
of Internal Affairs revealed that 21 (88%) patients are alive
with no evidence of recurrent disease or second primary.
They were followed in other hospitals or by their general
practitioners.
Fig. 2 – Survival curve of 23 Stage IIA seminoma patients.(self-limited)
 disease.
4.  Discussion
Despite the current use of lower radiation doses and smaller
ﬁeld sizes, our retrospective study conﬁrms the excellent out-
come of Stage IIA, non-bulky, seminoma that has remained
excellent over the long term. However, work-up after orchiec-
tomy demonstrated that about 15–20% have radiologically
involved para-aortic lymph nodes and 70% even small bulk
disease,5,6 albeit the number of Stage IIA disease patients
has been too small to mount Phase III studies of treatment,
and treatment decisions must be determined from single-
institution reports and retrospective studies. Since the end of
the 1980s, whole body CT scan evaluation has become rou-
tine. The use of PET-CT in the initial staging of seminoma is
still controversial7; however, its implementation in follow-up
and decision-making in post-chemo or radiotherapy residual
masses has been successfully proved.8
The issue of optimal radiation dose, total as well as daily
dose, remains controversial.9,10 A German Prospective Multi-
center Clinical Trial4 which enrolled 30 participating centers
and 66 Stage IIA patients found that 30 Gy yielded 100%
in-ﬁeld tumor control and compared favorably with total
doses (30–35 Gy, including boost) of previous reports in the
literature2,3,6 and also with the current literature.1,11 It seems
that only prospective studies, like the German Study, could
reveal the most appropriate dose/schedule for IIA patients.
Acute and late side effects were low in our series. Leading
pronounced problems in the past were severe gastrointestinal
symptoms when abdominal ﬁelds with total doses between
3000 and 4000 cGy were used. Only two patients developed
peptic ulcer disease and radiation-induced proctitis, cured
totally with conservative treatment. In their 2012 study, Halle-
meier et al.11 also reported a very infrequent acute and late
toxicity.All but four of our patients were treated with the “hockey-
stick” ﬁeld covering only para-aortic and ipsilateral common
iliac lymphatics. Our recent and others’ experience1,4 has
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roved that limitation of the target volume can reduce abso-
utely side effects such as gastrointestinal, bony and second
ancers, as well as reduce scatter dose to the contralateral
estis. Using clinical, anatomic landmarks and nodal/vascular
apping, Wilder et al.3 support placement of the superior bor-
er of all radiotherapy ﬁelds at T11/T12 and the inferior border
t the top of the acetabulum. An antero-posterior–postero-
nterior boost is delivered to the involved adenopathy with
 2 cm margin. Wilder et al.3 suggested that cranial reduction
f the superior border reduces the rate of cardiovascular and
ulmonary late side effects, and delivers a smaller dose to the
idneys, stomach and bowel, with a reduced risk of second
alignancies with no increased rates of relapse. Large studies
ave been done with the superior border at the top of the T11
ertebral body and even at T9/T10.1,10 Whole pelvis should be
onsidered only if lymphatic disruptions occur such as follow-
ng pelvic operation, inguinal hernia repair or surgery due to
al- or undescended testis.4,12 Prophylactic mediastinal and
eft supra-clavicular irradiation has been totally omitted due
o its non-contribution to survival and increased rate of sec-
ndary malignancies, such as lung and thyroid cancer, and of
ardiovascular diseases.3,5
Among the current radiotherapy strategies to improve
he therapeutic ratio in early stage seminoma are computed
omography-based traditional radiotherapy, bone-marrow-
paring intensity modulated radiotherapy (BMS-IMRT), reduc-
ng the dose to the small and large bowel, stomach,
ancreas and liver, and proton therapy.13–15 Proton therapy
as able to reduce acute and late treatment morbidity and
mprove therapeutic ratio through the “spread-out Bragg peak”
henomenon.14 Proton treatment reduced the mean dose
o abdominal and pelvic organs compared to 3-dimensional
onformal radiotherapy (3-DCRT) and IMRT with a resultant
ore favorable dose distribution with less risk to out-of-ﬁeld
adiation-induced malignancies.15 However, additional stud-
es are warranted to assess the clinical beneﬁt/disadvantage
f these techniques.
Three patients developed late side effects of radiation ther-
py (Table 2). Because of the clear anatomic location of the
nd and 3rd part of duodenum in the high-dose volume of the
ara-aortic ﬁeld, peptic ulcer is the most common side-effect.
unnlaugsson et al.16 reported a strong correlation between
he amount of small bowel irradiated to doses larger than
5 Gy and gastrointestinal side effects. Bamberg et al.17 found
cute gastrointestinal side effects more  prevalent in irradiated
tage II compared to irradiated Stage I patients that could be
ttributed to the additional boost or to larger total doses used
n the past. It is clear that dose reduction should translate
nto lower rates of acute and chronic side-effects. Efstathiou
nd Logothetis18 emphasized the risk factors for the increased
ncidence of second malignancies, such as high radiation dose,
oung age at diagnosis, extended survival, and long follow-up.
Only one case of radiation-induced carcinoma was
escribed (Table 2, patient 1). The patient was treated in 2002
ith the “inverted-Y” method amounting to a dose of 3000 cGy,
ith 600 cGy additional boost. Due to the exposure of the
ancreatic body and the stomach within the high-dose vol-
me,  such tumors have been described, albeit with doses
igher than 3000 cGy.19 The median age of our irradiated semi-
oma patients was 36 years (as was this patient), and theirtherapy 1 9 ( 2 0 1 4 ) 281–286 285
cumulative dose risk of developing solid cancers was 31% com-
pared to 23% in the general population. The overall relative risk
of radiation-induced second cancers in seminoma patients is
approximately 2 after 10 years,20 comparable to the relative
risk of chemotherapy which is 1.8, especially when more  than
4 cycles are given.19 If combined modality is given, the relative
risk is even higher.2,9 Pathologically, the pattern of increas-
ing risk of radiation-induced SPC suggests a direct radiogenic
effect, and Zilli et al.13 suggested contributing factors, such as
scatter dose, number of monitor units, and volume of normal
tissues receiving low-dose radiation.
5.  Conclusion
Comparing important current studies to our own experi-
ence, we suggest that Stage IIA seminoma patients should
be treated with a total dose of about 3000 cGy, including the
boost. Regular CT scan or PET-CT should be implemented in
the follow-up of these patients. Given the young age of our
patients, patients probably remain at risk for late sequelae
for the remainder of their lives and we recommend follow-up
for life.
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